Regeneron reports two-year diabetic retinopathy data of Eylea
Patients treated with Eylea experienced a reduction of at least 75% in the risk of the vision-threatening events. Credit: Laitr Keiows.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more